Prospective Evaluation of Different Methods for Volumetric Analysis on [
FDG PET
Hodgkin’s lymphoma
interim evaluation
method comparison
pediatric
response assessment
volumetric analysis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
21 Oct 2022
21 Oct 2022
Historique:
received:
30
08
2022
revised:
27
09
2022
accepted:
17
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Rationale: Therapy response evaluation by 18F-fluorodeoxyglucose PET/CT (FDG PET) has become a powerful tool for the discrimination of responders from non-responders in pediatric Hodgkin lymphoma (HL). Recently, volumetric analyses have been regarded as a valuable tool for disease prognostication and biological characterization in cancer. Given the multitude of methods available for volumetric analysis in HL, the AIEOP Hodgkin Lymphoma Study Group has designed a prospective analysis of the Italian cohort enrolled in the EuroNet-PHL-C2 trial. Methods: Primarily, the study aimed to compare the different segmentation techniques used for volumetric assessment in HL patients at baseline (PET1) and during therapy: early (PET2) and late assessment (PET3). Overall, 50 patients and 150 scans were investigated for the current analysis. A dedicated software was used to semi-automatically delineate contours of the lesions by using different threshold methods. More specifically, four methods were applied: (1) fixed 41% threshold of the maximum standardized uptake value (SUVmax) within the respective lymphoma site (V41%), (2) fixed absolute SUV threshold of 2.5 (V2.5); (3) SUVmax(lesion)/SUVmean liver >1.5 (Vliver); (4) adaptive method (AM). All parameters obtained from the different methods were analyzed with respect to response. Results: Among the different methods investigated, the strongest correlation was observed between AM and Vliver (rho > 0.9; p < 0.001 for SUVmean, MTV and TLG at all scan timing), along with V2.5 and AM or Vliver (rho 0.98, p < 0.001 for TLG at baseline; rho > 0.9; p < 0.001 for SUVmean, MTV and TLG at PET2 and PET3, respectively). To determine the best segmentation method, we applied logistic regression and correlated different results with Deauville scores at late evaluation. Logistic regression demonstrated that MTV (metabolic tumor volume) and TLG (total lesion glycolysis) computation according to V2.5 and Vliver significantly correlated to response to treatment (p = 0.01 and 0.04 for MTV and 0.03 and 0.04 for TLG, respectively). SUVmean also resulted in significant correlation as absolute value or variation. Conclusions: The best correlation for volumetric analysis was documented for AM and Vliver, followed by V2.5. The volumetric analyses obtained from V2.5 and Vliver significantly correlated to response to therapy, proving to be preferred thresholds in our pediatric HL cohort.
Identifiants
pubmed: 36294544
pii: jcm11206223
doi: 10.3390/jcm11206223
pmc: PMC9605658
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
BMC Cancer. 2018 May 3;18(1):521
pubmed: 29724189
Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S3-12
pubmed: 12734687
Cancer Sci. 2013 Dec;104(12):1656-61
pubmed: 24033666
Sci Rep. 2020 Jul 28;10(1):12590
pubmed: 32724136
Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):23-36
pubmed: 18719909
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):87-96
pubmed: 30276438
Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1620-7
pubmed: 21559977
Blood. 2018 Jan 4;131(1):84-94
pubmed: 29038339
Am J Nucl Med Mol Imaging. 2013 Apr 09;3(3):272-81
pubmed: 23638338
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1209-19
pubmed: 26902371
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2017-22
pubmed: 24902639
Leuk Lymphoma. 2009 Aug;50(8):1257-60
pubmed: 19544140
Metabolites. 2021 Jan 26;11(2):
pubmed: 33530590
Ann Nucl Med. 2019 Jul;33(7):449-458
pubmed: 30929200
J Nucl Med. 2009 Aug;50(8):1237-43
pubmed: 19617326
Lancet Oncol. 2022 Jan;23(1):125-137
pubmed: 34895479
Ann Oncol. 2011 May;22(5):1198-1203
pubmed: 20966182
J Nucl Med. 2019 Aug;60(8):1096-1102
pubmed: 30954945
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
J Clin Oncol. 2010 Aug 10;28(23):3680-6
pubmed: 20625128
Pediatr Radiol. 2004 Mar;34(3):190-8
pubmed: 14745528
BMJ Open. 2021 Mar 29;11(3):e041252
pubmed: 33782017
J Nucl Med. 2022 Sep;63(9):1424-1430
pubmed: 34992152
Nucl Med Mol Imaging. 2014 Sep;48(3):187-95
pubmed: 25177375
Cancer. 2013 Mar 15;119(6):1195-202
pubmed: 23212736
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):97-106
pubmed: 30219963
Skeletal Radiol. 2006 Aug;35(8):553-4
pubmed: 16699780
AJR Am J Roentgenol. 2006 Feb;186(2):581; author reply 581-2
pubmed: 16423975
Ann Nucl Med. 2018 Jul;32(6):410-416
pubmed: 29754276
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1301-8
pubmed: 24604592
Cancer Biother Radiopharm. 2008 Dec;23(6):681-90
pubmed: 19111053
J Clin Oncol. 2014 Sep 20;32(27):3048-58
pubmed: 25113771
Ann Nucl Med. 2018 Oct;32(8):532-541
pubmed: 29982990
Ann Hematol. 2020 Jun;99(6):1321-1330
pubmed: 32333153
Blood. 2018 May 31;131(22):2449-2453
pubmed: 29559480
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):97-110
pubmed: 28411336
J Clin Oncol. 2016 Oct 20;34(30):3618-3626
pubmed: 27551111
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):319-29
pubmed: 19756591
PLoS One. 2016 Mar 10;11(3):e0149072
pubmed: 26963909
PLoS One. 2015 Oct 16;10(10):e0140830
pubmed: 26473950
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Blood. 2018 Mar 29;131(13):1456-1463
pubmed: 29437590